5 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 1, 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
Follow this drug Literature Review of Phosphatidylinositol 3-Kinases trials Research Report on Phosphatidylinositol 3-Kinases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas ONC201, Radiation Therapy, Paxalisib - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 2 | Recruiting | University of California, San Francisco | 360 | 2021-10-20 | 2026-06-26 |
| Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects [14C]-Paxalisib Capsule - Healthy | Phase 1 | Completed | Kazia Therapeutics Limited | 6 | 2021-08-18 | 2024-03-15 |
| Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel - Body Weight Changes | Not applicable | Completed | Supplement Formulators, Inc. | 23 | 2017-11-14 | 2018-04-17 |
| Effect of Washing With Clove Extract on Inflammation and Infection Place Logging Shaldon Needle clove extract, Betadine - Renal Failure | Not applicable | Unknown | Mashhad University of Medical Sciences | 60 | 2016-08-01 | 2016-08-15 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies RP6530 - Lymphoma, B-Cell, T-Cell Lymphoma | Phase 1 | Completed | Rhizen Pharmaceuticals SA | 35 | 2013-11-01 | 2016-06-24 |
| Herbal Mouthrinse for Oral Mucositis Study Neem Mouthrinse, Placebo Mouthrinse - Oral Mucositis | Phase 2 | Completed | Medical University of South Carolina | 50 | 2013-07-01 | 2017-03-06 |
| Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor) - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | EMD Serono | 146 | 2011-05-01 | 2017-03-07 |
Breast Neoplasms (2) · Body Weight Changes (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Infections (1) · Inflammation (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Melanoma (1) · Mucositis (1) · Neoplasm Metastasis (1)
EMD Serono (1) · Kazia Therapeutics Limited (1) · Mashhad University of Medical Sciences (1) · Medical University of South Carolina (1) · Rhizen Pharmaceuticals SA (1) · Supplement Formulators, Inc. (1) · University of California, San Francisco (1) · University of Miami (1)
United States (5) · Italy (2) · Australia (1) · France (1) · Iran (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Ali Bazzi, MSc (1) · Carmelo Carlo-stella, MD (1) · Frances Valdes-Albini, MD (1) · Philip Evans, MBChB, MRCS (1) · Richard Delarue, MD (1) · Sabine Mueller, MD, PhD (1) · Steven Joyal, M.D. (1) · Susan G. Reed, DDS, DrPH (1)
PMID 18973181, PMID 22430697, PMID 23638291, PMID 33512717, PMID 35157764, PMID 37195023
R01NS124607 (1), R21CA158530 (1)